Swedish Orphan Biovitrum AB (publ) (BIOVF) Financials

BIOVF Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 8.5 billion 4.2 billion
March 31, 2026 8.5 billion 4.3 billion
Dec. 31, 2025 7.3 billion 3.2 billion
Sept. 30, 2025 7.1 billion 3.3 billion

BIOVF Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 161.9 million ?
March 31, 2026 91.1 million 7.5 million
Dec. 31, 2025 322.3 million 7.3 million
Sept. 30, 2025 193.2 million ?

BIOVF Net Income
Graph available only for paid members. Upgrade to see it.
DateNet Income
June 30, 2026 145.5 million
March 31, 2026 175.6 million
Dec. 31, 2025 201.7 million
Sept. 30, 2025 -305.2 million

BIOVF Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 111.4 million 873.6 million 39.0 million
March 31, 2026 98.2 million 799.5 million 39.8 million
Dec. 31, 2025 112.8 million 589.2 million 40.4 million
Sept. 30, 2025 109.6 million 925.4 million 27.9 million

BIOVF Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 36.1 million
March 31, 2026 36.5 million
Dec. 31, 2025 37.9 million
Sept. 30, 2025 36.6 million

BIOVF Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 35.0 million 117.7 million 172.7 million -
March 31, 2026 26.5 million 99.0 million 196.1 million -
Dec. 31, 2025 541676 95.2 million 321.9 million -
Sept. 30, 2025 849358 79.5 million -511.4 million -

BIOVF Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 807.6 million 188.4 million
March 31, 2026 750.4 million 182.5 million
Dec. 31, 2025 847.3 million 241.7 million
Sept. 30, 2025 819.8 million 953.2 million

BIOVF

Price: $49.03

52 week price:
28.94
49.03

Earnings Per Share: 0.40 USD

P/E Ratio: 122.57

Exchange: PNK

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Market Capitalization: 17.1 billion

Links: